Takeda Pharmaceutical ADR had its Relative Strength (RS) Rating upgraded from 64 to 71 Wednesday — a welcome improvement, but still short of the 80 or higher score you look for.
How To Invest In Stocks In Both Bull And Bear Markets
This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves. See if Takeda Pharmaceutical ADR can continue to show renewed price strength and hit that benchmark.
Takeda Pharmaceutical ADR is building a cup with handle with a 15.42 entry. See if the stock can clear the breakout price in volume at least 40% above average.
While the company's bottom line growth decreased in the company's most recent performance report from -21% to -33%, sales rose 1%, up from -8% in the prior report.
The company earns the No. 11 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and Indivior are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
